10 Stocks Under $10 that Will Triple

3. Relay Therapeutics, Inc (NASDAQ:RLAY)

Upside Potential: 490.23%

Number Of Hedge Funds: 37

Relay Therapeutics, Inc. (NASDAQ:RLAY) develops targeted treatments for cancer and genetic diseases. The company speeds up drug discovery using cutting-edge computational tools and experimental technologies. The company utilizes AI and ML to find new drugs by blending computing power with cutting-edge lab data. This gives a unique insight into how proteins move and behave, which helps the company discover promising candidates that can be used to create innovative therapies.

For FY24, Relay Therapeutics, Inc. (NASDAQ:RLAY) brought in $10 million in revenue, down from $25.5 million in 2023. The main reason for this decline was milestone payments from the company’s license agreements. However, Relay ended Q4 with $781.3 million in cash and investments, a substantial reserve to continue with the ongoing clinical trials. The R&D costs reached $319.1 million in 2024, slightly lower than the prior year, thanks to strategic prioritization, while the yearly net loss was $337.7 million, a small improvement from 2023.

Moreover, Relay’s late-stage cancer program continues to advance with a crucial clinical trial beginning in mid-2025. Early results look promising, showing better treatment responses and disease advancements. In addition, Relay Therapeutics, Inc. (NASDAQ:RLAY) is also exploring new drug combinations to improve effectiveness and increase treatment options.

Thus, Relay Therapeutics, Inc. (NASDAQ:RLAY) shows notable potential with steady cash reserves to fund its clinical programs, ongoing cancer research progress, and growing treatment possibilities. These factors make Relay one of the 10 stocks that will triple.